Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Surface-Mediated Defenses Against Injury

Surface-Mediated Defenses Against Injury Abstract Since the late 1950s, we have come to learn that many of the defenses of the body against injury are interdependent, and that such protective devices as clotting, fibrinolysis, inflammation, and immunologic reactions are not separable phenomena but rather are different facets of one intertwining mechanism. As a coagulationist, I shall support this view by focusing on what I know about an unusual clotting factor, Hageman factor, but I could equally well use as a starting point the complexities of platelet function, or complement, or the systems that generate biologically active polypeptides such as bradykinin. For two centuries, investigators have marveled that blood, fluid within our vessels, clots when it is shed. About 100 years ago, John Lister,1 better known for other things, made the remarkable observation that shed blood clotted much faster in a porcelain dish than in an india-rubber tube. His very modern conclusion was that clotting References 1. Lister J: On the coagulation of the blood . Proc R Soc 1863;12:580-611.Crossref 2. Bordet J, Gengou O: Recherches sur la coagulation du sang et les sérum anticoagulants . Am Inst Pasteur 1901;15:124-144. 3. Ratnoff OD, Colopy JE: A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma . J Clin Invest 1955;34:602-613.Crossref 4. Ratnoff OD, Rosenblum JM: Role of Hageman factor in the initiation of clotting by glass . Am J Med 1958;25:160-168.Crossref 5. Ratnoff OD, Saito H: Surface-mediated reactions , Piomelli S, Yachnin S (eds): In Current Topics in Hematology . New York, Alan R Liss, 1979, vol 2, pp 1-57. 6. Revak SO, Cochrane CP, Johnston AR, et al: Structural changes accompanying enzymatic activation of human Hageman factor . J Clin Invest 1974;54:619-627.Crossref 7. Kaplan AP, Austen KF: A pre-albumin activator of prekallikrein . J Immunol 1970;105:802-811. 8. Revak SD, Cochrane CG, Griffin JH: The binding and cleavage characteristics of human Hageman factor during contact activation: A comparison of normal plasma with plasma deficient in factor XI, prekallikrein or high molecular weight kininogen . J Clin Invest 1977;59:1167-1175.Crossref 9. Ratnoff OD, Saito H: Amidolytic properties of single-chain activated Hageman factor . Proc Natl Acad Sci USA 1979;76:1461-1463.Crossref 10. Ratonoff OD, Saito H: The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid . J Lab Clin Med 1982;100:248-260. 11. Schiffman S, Rapaport SI, Ware AG, et al: Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma . Proc Soc Exp Biol Med 1960;105:453-455.Crossref 12. Abelous JE, Bardier E: Les substances hypotensive de l'urine humaine normale . CR Soc Biol 1909;66:511-512. 13. Werle E: History of kallikrein and some aspects of its chemistry and physiology , Haberland GL, Rohen JW (eds): in Kininogenases-Kallikrein: First Symposium on Physiological Properties and Pharmacological Rationale . Stuttgart, West Germany, FK Schittauer Verlag, 1973, pp 7-22. 14. Kraut H, Frey EK, Bauer E: Ueber ein neues Kreislaufhormon . Z Physiol Chem 1928;175:97-114.Crossref 15. Vogt W: Demonstration of the presence of two separate kinin-forming systems in human and other plasma , Erdos EG, Back N, Sicuteri F (eds): in Hypotensive Peptides. New York , Springer Verlag, 1966, pp 185-192. 16. Margolis J: Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation . J Physiol 1958;144:1-22. 17. Armstrong D, Keele CA, Jepson JB, et al: Development of pain-producing substance in human plasma . Nature 1954;174:791-792.Crossref 18. Webster ME, Ratnoff OD: Role of Hageman factor in the activation of vasodilator activity in human plasma . Nature 1961;192:180-181.Crossref 19. Mandle R Jr, Kaplan AP: Hageman factor substrates: Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis . J Biol Chem 1977;252:6097-6104. 20. Goldsmith JH Jr, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments . J Clin Invest 1978;62:54-60.Crossref 21. Vogt WJ: Kinin formation by plasmin, an indirect process mediated by activation of kallikrein . J Physiol 1964;170;153-166. 22. Back N, Steger R: Activation of bovine bradykininogen by human plasmin . Life Sci 1965;4:153-157.Crossref 23. Lepow IH, Ratnoff OD, Levy R: Studies on the activation of a proesterase associated with partially purified first component of human complement . J Exp Med 1958;107:451-474.Crossref 24. Ward PA: A plasmin-split fragment of C′3 as a new chemotactic factor . J Exp Med 1967;121:189-206.Crossref 25. Kaplan AP, Austen KF: A prealbumin activator of prekalikrein: II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin . J Exp Med 1971; 133:696-712.Crossref 26. Hathaway WE, Belhasen LP, Hathaway HS: Evidence for a new plasma thromboplastin factor: I. Case report, coagulation studies and physiochemical properties . Blood 1965;26:521-532. 27. Saito H, Ratnoff OD, Waldmann R, et al: Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability . J Clin Invest 1975;55:1082-1089.Crossref 28. Colman RW, Bagdasarian A, Talamo RC, et al: Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways . J Clin Invest 1975;56:1650-1662.Crossref 29. Wuepper KD, Miller DR, Lacombe MJ: Flaujeac trait: Deficiency of human plasma kininogen . J Clin Invest 1975;56:1663-1672.Crossref 30. Wuepper KD: Biochemistry and biology of components of the plasma kinin-forming system , Lepow IH, Ward PA (eds): in Inflammation: Mechanisms and Control . New York, Academic Press Inc, 1972, pp 93-117. 31. Donaldson VH, Glueck HI, Miller MA, et al: Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibronlysis . J Lab Clin Med 1976;87:327-337. 32. Kellermeyer RW, Warren KS: The role of chemical mediators in the inflammatory response induced by foreign bodies: Comparison with the schistosome egg granuloma . J Exp Med 1970;131:21-39.Crossref 33. Wendt PE, Puro HE, Shapiro J, et al: Angiothrombotic pulmonary hypertension in addicts: "Blue velvet" addiction . JAMA 1964;188:755-757.Crossref 34. Gordon EM, Ratnoff OD, Saito H, et al: Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral anticoagulants . J Lab Clin Med 1980;96:762-769. 35. Gordon EM, Donaldson VH, Saito H, et al: Reduced titer of Hageman factor (factor XII) in Orientals . Ann Intern Med 1981;95:697-700.Crossref 36. Dolovich J, Back H, Arbesman CE: The presence of bradykininlike activity in nasal secretion from allergic subjects , abstracted. J Allergy Clin Immunol 1968;41:103. 37. Michel B, Russell T, Winkelmann RK, et al: Release of kinins during wheal and flare allergic skin reactions . J Clin Invest 1968;47:68. 38. DeLaus FV, Winkelmann RK: Kinins in cold urticaria . Arch Dermatol 1968;98:67-74.Crossref 39. Ate K, Watanabe N, Kumagai N, et al: Circulatory plasma kinin in patients with bronchial asthma . Experientia 1967;23:626-627.Crossref 40. Oates JA, Melmon K, Sjoerdsma A, et al: Release of a kinin peptide in the carcinoid syndrome . Lancet 1964;1:514-517.Crossref 41. Armstrong D, Jepson JS, Keele CA, et al: Pain-producing substance in human inflammatory exudates and plasma . J Physiol 1957;135:350-370. 42. Schwartz HJ, Zimmerman TS: The effect of ellagic acid on delayed hypersensitivity reactions in guinea pigs . J Immunol 1971;106:450-453. 43. Johasson O, Becker EL: Release of kallikrein from guinea pig lung during anaphylaxis . J Exp Med 1966;123:509-522.Crossref 44. Beraldo WT: Formation of bradykinin in anaphylactic and peptone shock . Am J Physiol 1950;163:283-289. 45. Ratnoff OD, Nossel HL: Wasp sting anaphylaxis . Blood , in press. 46. Donaldson VH, Evans RR: A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C′1-esterase . Am J Med 1963;35:37-44.Crossref 47. Donaldson VH, Rosen FS: Action of complement in hereditary angioneurotic edema: The role of C′1-esterase . J Clin Invest 1964;43:2204-2212.Crossref 48. Donaldson VH, Ratnoff OD, Dias da Silva W, et al: Permeability-increasing activity in hereditary angioneurotic edema plasma: II. Mechanism of formation and partial characterization . J Clin Invest 1969;48:642-653.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Surface-Mediated Defenses Against Injury

Archives of Dermatology , Volume 119 (5) – May 1, 1983

Loading next page...
 
/lp/american-medical-association/surface-mediated-defenses-against-injury-HCa3zt0lqF
Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1983.01650290072021
Publisher site
See Article on Publisher Site

Abstract

Abstract Since the late 1950s, we have come to learn that many of the defenses of the body against injury are interdependent, and that such protective devices as clotting, fibrinolysis, inflammation, and immunologic reactions are not separable phenomena but rather are different facets of one intertwining mechanism. As a coagulationist, I shall support this view by focusing on what I know about an unusual clotting factor, Hageman factor, but I could equally well use as a starting point the complexities of platelet function, or complement, or the systems that generate biologically active polypeptides such as bradykinin. For two centuries, investigators have marveled that blood, fluid within our vessels, clots when it is shed. About 100 years ago, John Lister,1 better known for other things, made the remarkable observation that shed blood clotted much faster in a porcelain dish than in an india-rubber tube. His very modern conclusion was that clotting References 1. Lister J: On the coagulation of the blood . Proc R Soc 1863;12:580-611.Crossref 2. Bordet J, Gengou O: Recherches sur la coagulation du sang et les sérum anticoagulants . Am Inst Pasteur 1901;15:124-144. 3. Ratnoff OD, Colopy JE: A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma . J Clin Invest 1955;34:602-613.Crossref 4. Ratnoff OD, Rosenblum JM: Role of Hageman factor in the initiation of clotting by glass . Am J Med 1958;25:160-168.Crossref 5. Ratnoff OD, Saito H: Surface-mediated reactions , Piomelli S, Yachnin S (eds): In Current Topics in Hematology . New York, Alan R Liss, 1979, vol 2, pp 1-57. 6. Revak SO, Cochrane CP, Johnston AR, et al: Structural changes accompanying enzymatic activation of human Hageman factor . J Clin Invest 1974;54:619-627.Crossref 7. Kaplan AP, Austen KF: A pre-albumin activator of prekallikrein . J Immunol 1970;105:802-811. 8. Revak SD, Cochrane CG, Griffin JH: The binding and cleavage characteristics of human Hageman factor during contact activation: A comparison of normal plasma with plasma deficient in factor XI, prekallikrein or high molecular weight kininogen . J Clin Invest 1977;59:1167-1175.Crossref 9. Ratnoff OD, Saito H: Amidolytic properties of single-chain activated Hageman factor . Proc Natl Acad Sci USA 1979;76:1461-1463.Crossref 10. Ratonoff OD, Saito H: The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid . J Lab Clin Med 1982;100:248-260. 11. Schiffman S, Rapaport SI, Ware AG, et al: Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma . Proc Soc Exp Biol Med 1960;105:453-455.Crossref 12. Abelous JE, Bardier E: Les substances hypotensive de l'urine humaine normale . CR Soc Biol 1909;66:511-512. 13. Werle E: History of kallikrein and some aspects of its chemistry and physiology , Haberland GL, Rohen JW (eds): in Kininogenases-Kallikrein: First Symposium on Physiological Properties and Pharmacological Rationale . Stuttgart, West Germany, FK Schittauer Verlag, 1973, pp 7-22. 14. Kraut H, Frey EK, Bauer E: Ueber ein neues Kreislaufhormon . Z Physiol Chem 1928;175:97-114.Crossref 15. Vogt W: Demonstration of the presence of two separate kinin-forming systems in human and other plasma , Erdos EG, Back N, Sicuteri F (eds): in Hypotensive Peptides. New York , Springer Verlag, 1966, pp 185-192. 16. Margolis J: Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation . J Physiol 1958;144:1-22. 17. Armstrong D, Keele CA, Jepson JB, et al: Development of pain-producing substance in human plasma . Nature 1954;174:791-792.Crossref 18. Webster ME, Ratnoff OD: Role of Hageman factor in the activation of vasodilator activity in human plasma . Nature 1961;192:180-181.Crossref 19. Mandle R Jr, Kaplan AP: Hageman factor substrates: Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis . J Biol Chem 1977;252:6097-6104. 20. Goldsmith JH Jr, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments . J Clin Invest 1978;62:54-60.Crossref 21. Vogt WJ: Kinin formation by plasmin, an indirect process mediated by activation of kallikrein . J Physiol 1964;170;153-166. 22. Back N, Steger R: Activation of bovine bradykininogen by human plasmin . Life Sci 1965;4:153-157.Crossref 23. Lepow IH, Ratnoff OD, Levy R: Studies on the activation of a proesterase associated with partially purified first component of human complement . J Exp Med 1958;107:451-474.Crossref 24. Ward PA: A plasmin-split fragment of C′3 as a new chemotactic factor . J Exp Med 1967;121:189-206.Crossref 25. Kaplan AP, Austen KF: A prealbumin activator of prekalikrein: II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin . J Exp Med 1971; 133:696-712.Crossref 26. Hathaway WE, Belhasen LP, Hathaway HS: Evidence for a new plasma thromboplastin factor: I. Case report, coagulation studies and physiochemical properties . Blood 1965;26:521-532. 27. Saito H, Ratnoff OD, Waldmann R, et al: Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability . J Clin Invest 1975;55:1082-1089.Crossref 28. Colman RW, Bagdasarian A, Talamo RC, et al: Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways . J Clin Invest 1975;56:1650-1662.Crossref 29. Wuepper KD, Miller DR, Lacombe MJ: Flaujeac trait: Deficiency of human plasma kininogen . J Clin Invest 1975;56:1663-1672.Crossref 30. Wuepper KD: Biochemistry and biology of components of the plasma kinin-forming system , Lepow IH, Ward PA (eds): in Inflammation: Mechanisms and Control . New York, Academic Press Inc, 1972, pp 93-117. 31. Donaldson VH, Glueck HI, Miller MA, et al: Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibronlysis . J Lab Clin Med 1976;87:327-337. 32. Kellermeyer RW, Warren KS: The role of chemical mediators in the inflammatory response induced by foreign bodies: Comparison with the schistosome egg granuloma . J Exp Med 1970;131:21-39.Crossref 33. Wendt PE, Puro HE, Shapiro J, et al: Angiothrombotic pulmonary hypertension in addicts: "Blue velvet" addiction . JAMA 1964;188:755-757.Crossref 34. Gordon EM, Ratnoff OD, Saito H, et al: Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral anticoagulants . J Lab Clin Med 1980;96:762-769. 35. Gordon EM, Donaldson VH, Saito H, et al: Reduced titer of Hageman factor (factor XII) in Orientals . Ann Intern Med 1981;95:697-700.Crossref 36. Dolovich J, Back H, Arbesman CE: The presence of bradykininlike activity in nasal secretion from allergic subjects , abstracted. J Allergy Clin Immunol 1968;41:103. 37. Michel B, Russell T, Winkelmann RK, et al: Release of kinins during wheal and flare allergic skin reactions . J Clin Invest 1968;47:68. 38. DeLaus FV, Winkelmann RK: Kinins in cold urticaria . Arch Dermatol 1968;98:67-74.Crossref 39. Ate K, Watanabe N, Kumagai N, et al: Circulatory plasma kinin in patients with bronchial asthma . Experientia 1967;23:626-627.Crossref 40. Oates JA, Melmon K, Sjoerdsma A, et al: Release of a kinin peptide in the carcinoid syndrome . Lancet 1964;1:514-517.Crossref 41. Armstrong D, Jepson JS, Keele CA, et al: Pain-producing substance in human inflammatory exudates and plasma . J Physiol 1957;135:350-370. 42. Schwartz HJ, Zimmerman TS: The effect of ellagic acid on delayed hypersensitivity reactions in guinea pigs . J Immunol 1971;106:450-453. 43. Johasson O, Becker EL: Release of kallikrein from guinea pig lung during anaphylaxis . J Exp Med 1966;123:509-522.Crossref 44. Beraldo WT: Formation of bradykinin in anaphylactic and peptone shock . Am J Physiol 1950;163:283-289. 45. Ratnoff OD, Nossel HL: Wasp sting anaphylaxis . Blood , in press. 46. Donaldson VH, Evans RR: A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C′1-esterase . Am J Med 1963;35:37-44.Crossref 47. Donaldson VH, Rosen FS: Action of complement in hereditary angioneurotic edema: The role of C′1-esterase . J Clin Invest 1964;43:2204-2212.Crossref 48. Donaldson VH, Ratnoff OD, Dias da Silva W, et al: Permeability-increasing activity in hereditary angioneurotic edema plasma: II. Mechanism of formation and partial characterization . J Clin Invest 1969;48:642-653.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: May 1, 1983

References